Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Sees Strong Trading Volume

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) saw strong trading volume on Thursday . Approximately 7,232 shares changed hands during mid-day trading, a decline of 30% from the previous session’s volume of 10,269 shares.The stock last traded at $38.61 and had previously closed at $38.45.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a “neutral” rating and set a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Citigroup restated a “neutral” rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a report on Friday, May 31st. Jefferies Financial Group reissued a “hold” rating and set a $39.00 price objective (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Stifel Nicolaus reaffirmed a “hold” rating and issued a $40.00 target price (down from $55.00) on shares of Calliditas Therapeutics AB (publ) in a research report on Tuesday, May 28th. Finally, Lifesci Capital lowered Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 28th. Six equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, Calliditas Therapeutics AB (publ) currently has a consensus rating of “Hold” and a consensus target price of $35.00.

Calliditas Therapeutics AB (publ) Stock Up 0.7 %

The company has a current ratio of 2.69, a quick ratio of 2.62 and a debt-to-equity ratio of 8.46. The firm has a 50-day moving average of $37.98 and a 200 day moving average of $27.10. The stock has a market capitalization of $1.15 billion, a price-to-earnings ratio of -20.78 and a beta of 1.77.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last announced its earnings results on Thursday, May 23rd. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.74). The firm had revenue of $28.43 million during the quarter, compared to analysts’ expectations of $35.78 million. Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. On average, sell-side analysts anticipate that Calliditas Therapeutics AB will post -0.86 earnings per share for the current year.

Institutional Trading of Calliditas Therapeutics AB (publ)

A hedge fund recently bought a new stake in Calliditas Therapeutics AB (publ) stock. Optiver Holding B.V. purchased a new position in shares of Calliditas Therapeutics AB (publ) (NASDAQ:CALT) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 980 shares of the company’s stock, valued at approximately $25,000. Institutional investors own 2.83% of the company’s stock.

Calliditas Therapeutics AB (publ) Company Profile

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.